Program
nirogacestat
Also written as “PF-03084014”, “Nirogacestat” and “Nirogacestat oral tablet”.
Its studies are mostly in Multiple Myeloma · Desmoid Tumors · Ovarian Neoplasms · Leukemia · Breast Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 62 open or running | phase 4since Jul 31, 2025 | Dec 17, 2018 | May 28, 2027phase 2 · NCT07170644 |
| Pfizer | 60 open or running | phase 2since Apr 2, 2014 | Apr 6, 2009 | none ahead |
| GlaxoSmithKline | 33 open or running | phase 2since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| Precision BioSciences | 10 open or running | phase 1since Nov 12, 2019 | Nov 12, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 6, 2009.
- Jun 10, 2013Phase 1 study in Breast Cancer MetastaticPfizer · NCT01876251 · 30 enrolled · United States, Belgium, Italy and more
- Apr 2, 2014Phase 2 study in Pancreatic NeoplasmsPfizer · NCT02109445 · 3 enrolled · United States
- Nov 20, 2014Phase 2 study in Triple Negative Breast NeoplasmsPfizer · NCT02299635 · 19 enrolled · United States, Hungary, Italy and more
- Jun 2, 2015Phase 1 study in Advanced Solid TumorsPfizer · NCT02462707
- Dec 17, 2018Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Desmoid TumorsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03785964 · 142 enrolled · United States, Belgium, Canada and more
- Nov 12, 2019Precision BioSciences's first study: phase 1 study in Multiple MyelomaNew to Precision BioSciencesPrecision BioSciences · NCT04171843 · 48 enrolled · United States
- Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
- Apr 13, 2022Phase 2 study in Granulosa cell tumor of the ovaryMerck KGaA, Darmstadt, Germany · NCT05348356 · 53 enrolled · United States, Canada, Poland
- Jul 22, 2025GlaxoSmithKline's first study: phase 2 study in Multiple MyelomaNew to GlaxoSmithKlineGlaxoSmithKline · NCT07084896 · 106 enrolled · United States, Australia, Canada and more
- Jul 31, 2025Phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689 · 50 planned · Belgium, Germany, Italy and more
- Jul 31, 2025Phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644 · 20 enrolled · Japan
- Aug 7, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07171619 · 24 enrolled · United States
- Aug 25, 20252 phase 2 studies in Multiple MyelomaGlaxoSmithKline · NCT07150104, NCT07150091
- Nov 19, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07259330 · 20 enrolled · Netherlands
Ahead
- May 28, 2027Primary completion: phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644
- Feb 26, 2031Primary completion: phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689
TargetBeta
“Gamma-secretase inhibitor; Gamma-secretase inhibitor”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07259330Healthy · Netherlands | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 27, 2026 | 20 |
| NCT07150104Multiple Myeloma · Brazil, Canada, France and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 14 |
| NCT07150091Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 20 |
| NCT07171619Healthy · United States | 1 | Completed | Merck KGaA, Darmstadt, Germany | Nov 10, 2025 | 24 |
| NCT07176689Desmoid Tumors · Belgium, Germany, Italy and more | 4 | Recruiting | Merck KGaA, Darmstadt, Germany | Feb 26, 2031 | 50 |
| NCT07170644Desmoid Tumors · Japan | 2 | Active, not recruiting | Merck KGaA, Darmstadt, Germany | May 28, 2027 | 20 |
| NCT07084896Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 106 |
| NCT05348356Granulosa cell tumor of the ovary · United States, Canada, Poland | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jul 8, 2025 | 53 |
| NCT05090566Multiple Myeloma · United States, Canada | 2 | Terminated | Pfizer | Feb 13, 2025 | 46 |
| NCT04171843Multiple Myeloma · United States | 1 | Terminated | Precision BioSciences | Oct 19, 2022 | 48 |
| NCT03785964Desmoid Tumors · United States, Belgium, Canada and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Apr 7, 2022 | 142 |
| NCT02462707Advanced Solid Tumors | 1 | Withdrawn | Pfizer | Jun 2016 | 0 |
| NCT02299635Triple Negative Breast Neoplasms · United States, Hungary, Italy and more | 2 | Terminated | Pfizer | Jan 14, 2016 | 19 |
| NCT02109445Pancreatic Neoplasms · United States | 2 | Terminated | Pfizer | Nov 6, 2014 | 3 |
| NCT01876251Breast Cancer Metastatic · United States, Belgium, Italy and more | 1 | Terminated | Pfizer | Dec 24, 2015 | 30 |
| NCT00878189Neoplasms by Histologic Type · United States, Italy | 1 | Completed | Pfizer | Jan 10, 2013 | 72 |
How it is read
Names in the registry
- “PF-03084014”, 10 entries
- “Nirogacestat”, 7 entries
- “Nirogacestat oral tablet”, 2 entries
- “Nirogacestat and Famotidine”, 1 entry
- “Nirogacestat and Rabeprazole”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Desmoid Tumors, 3 studies
- Ovarian Neoplasms, 1 study
- Leukemia, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.